Oral-administered allomelanin-like nanomedicine with multi-enzyme mimesis and favorable gastrointestinal tolerance for amelioration of acute colitis
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanoparticles: synthesis and applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (59)
Show source-provided references
1. Pathway paradigms revealed from the genetics of inflammatory bowel disease10.1038/s41586-020-2025-2 ↗
2. Ulcerative colitis10.1016/S0140-6736(16)32126-2 ↗
3. Understanding and preventing the global increase of inflammatory bowel disease10.1053/j.gastro.2016.10.020 ↗
4. Ulcerative colitis10.1038/s41572-020-0205-x ↗
5. Current and emerging therapeutic targets for IBD10.1038/nrgastro.2016.208 ↗
6. Nanoparticle-based oral drug delivery systems targeting the colon for treatment of ulcerative colitis10.1093/ibd/izy123 ↗
7. Rational combination therapy to overcome the plateau of drug efficacy in inflammatory bowel disease10.1053/j.gastro.2021.04.068 ↗
8. Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?10.1038/s41575-022-00604-y ↗
9. Intestinal homeostasis and its breakdown in inflammatory bowel disease10.1038/nature10208 ↗
10. Immunopathogenesis of IBD: current state of the art10.1038/nrgastro.2015.186 ↗
11. Ulcerative colitis10.1016/S0140-6736(12)60150-0 ↗
12. Intestinal barriers protect against disease10.1126/science.aat0835 ↗
13. Dynamic properties of the intestinal ecosystem call for combination therapies, targeting inflammation and microbiota, in ulcerative colitis10.1053/j.gastro.2021.08.057 ↗
14. SOD1 suppresses pro-inflammatory immune responses by protecting against oxidative stress in colitis10.1016/j.redox.2020.101760 ↗
15. Oxidative stress: an essential factor in the pathogenesis of gastrointestinal mucosal diseases10.1152/physrev.00040.2012 ↗
16. Mo(3)Se(4) nanoparticle with ROS scavenging and multi-enzyme activity for the treatment of DSS-induced colitis in mice10.1016/j.redox.2022.102441 ↗
17. Integrated cascade nanozyme catalyzes in vivo ROS scavenging for anti-inflammatory therapy10.1126/sciadv.abb2695 ↗
18. A valence-engineered self-cascading antioxidant nanozyme for the therapy of inflammatory bowel disease
19. Oral zero-valent-molybdenum nanodots for inflammatory bowel disease therapy10.1126/sciadv.abp9882 ↗
20. Melanin-like nanomaterials for advanced biomedical applications: a versatile platform with extraordinary promise
21. Novel intrapolymerization doped manganese-eumelanin coordination nanocomposites with ultrahigh relaxivity and their application in tumor theranostics10.1002/advs.201800032 ↗
22. Biomimetic manganese-eumelanin nanocomposites for combined hyperthermia-immunotherapy against prostate cancer10.1186/s12951-022-01248-5 ↗
23. Eumelanin-Fe(3)O(4) hybrid nanoparticles for enhanced MR/PA imaging-assisted local photothermolysis10.1039/C8BM00003D ↗
24. Dopamine-derived nanoparticles for the protection of irradiation-induced intestinal injury by maintaining intestinal homeostasis10.1039/D1BM02026A ↗
25. Comprehensive insights into the multi-antioxidative mechanisms of melanin nanoparticles and their application to protect brain from injury in ischemic stroke10.1021/jacs.6b11013 ↗
26. Intrinsically bioactive manganese-eumelanin nanocomposites mediated antioxidation and anti-neuroinflammation for targeted theranostics of traumatic brain injury
27. A MELANIN-BASED NATURAL ANTIOXIDANT DEFENSE NANOSYSTEM FOR THERANOSTIC APPLICATION IN ACUTE KIDNEY INJUry10.1002/adfm.201904833 ↗
28. Site-specific biomimicry of antioxidative melanin formation and its application for acute liver injury therapy and imaging10.1002/adma.202102391 ↗
29. Polydopamine nanoparticles attenuate retina ganglion cell degeneration and restore visual function after optic nerve injury10.1186/s12951-021-01199-3 ↗
30. Dopamine-melanin nanoparticles scavenge reactive oxygen and nitrogen species and activate autophagy for osteoarthritis therapy10.1039/C9NR03060C ↗
31. Polydopamine nanoparticles as efficient scavengers for reactive oxygen species in periodontal disease10.1021/acsnano.8b04022 ↗
32. Auid-orcid, rational design of orally administered cascade nanozyme for inflammatory bowel disease therapy10.1002/adma.202304967 ↗
33. Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease10.1186/s12951-023-01770-0 ↗
34. Orally deliverable strategy based on microalgal biomass for intestinal disease treatment10.1126/sciadv.abi9265 ↗
35. Allomelanin: a biopolymer of intrinsic microporosity10.1021/jacs.1c00748 ↗
36. Artificial allomelanin nanoparticles10.1021/acsnano.9b02160 ↗
37. Characterization and fate of hydrogen-bonded free-radical intermediates and their coupling products from the hydrogen atom transfer agent 1,8-naphthalenediol10.1021/acsomega.8b00155 ↗
38. Anisotropic synthetic allomelanin materials via solid-state polymerization of self-assembled 1,8-dihydroxynaphthalene dimers10.1002/anie.202103447 ↗
39. Programmable probiotics modulate inflammation and gut microbiota for inflammatory bowel disease treatment after effective oral delivery10.1038/s41467-022-31171-0 ↗
40. Engineered E. coli Nissle 1917 for the delivery of matrix-tethered therapeutic domains to the gut10.1038/s41467-019-13336-6 ↗
41. Dextran sulfate sodium (DSS)-induced colitis in mice10.1002/0471142735.im1525s104 ↗
42. Interferon gamma counteracts the angiogenic switch and induces vascular permeability in dextran sulfate sodium colitis in mice
43. Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease10.1016/j.nantod.2017.08.006 ↗
44. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease10.1016/j.cell.2018.08.067 ↗
45. IBD: selective nanoparticle adhesion can enhance colitis therapy10.1038/nrgastro.2010.66 ↗
46. Highly sensitive magnetic particle imaging of vulnerable atherosclerotic plaque with active myeloperoxidase-targeted nanoparticles10.7150/thno.49812 ↗
47. Sensitive magnetic particle imaging of haemoglobin degradation for the detection and monitoring of intraplaque haemorrhage in atherosclerosis10.1016/j.ebiom.2023.104509 ↗
48. STAT3-mediated ferroptosis is involved in ulcerative colitis10.1016/j.freeradbiomed.2022.06.242 ↗
49. E3 ligase c-Cbl regulates intestinal inflammation through suppressing fungi-induced noncanonical NF-κB activation10.1126/sciadv.abe5171 ↗
50. Avertin affects murine colitis by regulating neutrophils and macrophages10.1016/j.intimp.2019.106153 ↗
51. Genetics and pathogenesis of inflammatory bowel disease10.1038/nature10209 ↗
52. Neutrophil recruitment and function in health and inflammation10.1038/nri3399 ↗
53. Novel prognostic biomarkers of mucosal healing in ulcerative colitis patients treated with anti-TNF: neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio10.1093/ibd/izaa062 ↗
54. Myeloperoxidase: a versatile mediator of endothelial dysfunction and therapeutic target during cardiovascular disease10.1016/j.pharmthera.2020.107711 ↗
55. Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD10.1038/s41575-019-0172-4 ↗
56. Mechanisms regulating intestinal barrier integrity and its pathological implications10.1038/s12276-018-0126-x ↗
57. IFN-γ drives inflammatory bowel disease pathogenesis through VE-cadherin-directed vascular barrier disruption10.1172/JCI124884 ↗
58. Colonic epithelial cell diversity in health and inflammatory bowel disease10.1038/s41586-019-0992-y ↗
59. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery10.1038/nrd4333 ↗